Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00713960
Other study ID # NIS-CDK-DUM-2008/1
Secondary ID
Status Completed
Phase N/A
First received July 10, 2008
Last updated January 13, 2012
Start date April 2008
Est. completion date December 2010

Study information

Verified date January 2012
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection Agency
Study type Observational

Clinical Trial Summary

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice


Recruitment information / eligibility

Status Completed
Enrollment 2193
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

- Patients who suffer from diabetic nephropathy will be excluded

- According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Research Site Albertslund
Denmark Research Site Arhus C
Denmark Research site Assens
Denmark Research Site Billund
Denmark Research Site Brabrand
Denmark Research Site Erslev
Denmark Research Site Esbjerg
Denmark Research Site Faaborg
Denmark Research Site Gentofte
Denmark Research Site Give
Denmark Research Site Greve
Denmark Research Site Hadsund
Denmark Research Site Hedehusene
Denmark Research Site Helsingor
Denmark Research Site Hillerod
Denmark Research Site Hinnerup
Denmark Research Site Hjallerup
Denmark Research Site Hjorring
Denmark Research Site Hobro
Denmark Research Site Holaek
Denmark Research Site Holstebro
Denmark Research Site Horning
Denmark Research Site Hornsyld
Denmark Research Site Horsens
Denmark Research Site Karup J
Denmark Research Site Kbh. O
Denmark Research Site Kerteminde
Denmark Research Site Kjellerup
Denmark Research Site Klarup
Denmark Research Site Kobenhavn O
Denmark Research site Kobenhavn V
Denmark Research Site Koge
Denmark Research Site Kolding
Denmark Research Site Kolding C
Denmark Research Site Kongens Lyngby
Denmark Research Site Lemvig
Denmark Research Site Lystrup
Denmark Research Site Maribo
Denmark Research Site Naestved
Denmark Research Site Niva
Denmark Research Site Odense C
Denmark Research Site Pandrup
Denmark Research Site Randers
Denmark Research Site Ringsted
Denmark Research Site Rodding
Denmark Research Site Roskilde
Denmark Research Site Rungsted Kyst
Denmark Research Site Silkeborg
Denmark Research Site Skaelskor
Denmark Research Site Solrod Strand
Denmark Research Site Sonder-Felding
Denmark Research Site Sonderborg
Denmark Research Site Stege
Denmark Research Site Struer
Denmark Research Site Svendborg
Denmark Research Site Svinninge
Denmark Research Site Thisted
Denmark Research Site Tune
Denmark Research Site Vamdrup
Denmark Research Site Varde
Denmark Research Site Vejen
Denmark Research Site Vejle
Denmark Research Site Vestervig
Denmark Research Site Viborg
Denmark Research Site Viby J
Denmark Research Site Vivild

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken As needed, min. baseline and after 6 months No
Secondary Number of visits pr. patients, drop-out Annually No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment